中华器官移植杂志
中華器官移植雜誌
중화기관이식잡지
CHINESE JOURNAL OF ORGAN TRANSPLANTATION
2012年
2期
118-122
,共5页
蓝柳根%卢景宁%陈滨%彭民浩
藍柳根%盧景寧%陳濱%彭民浩
람류근%로경저%진빈%팽민호
大鼠%肝移植%厄贝沙坦%依达拉奉%门静脉压%再灌注损伤
大鼠%肝移植%阨貝沙坦%依達拉奉%門靜脈壓%再灌註損傷
대서%간이식%액패사탄%의체랍봉%문정맥압%재관주손상
Rats%Liver transplantation%Irbesartan%Edaravone%Portal pressure%Ischemia reperfusion injury
目的 探讨联合使用厄贝沙坦和依达拉奉在大鼠小体积供肝移植早期中对移植肝的保护作用及机制.方法 取体重相差20～30g的150对SD大鼠作为肝移植供、受者,其中小体重大鼠作为供者.按随机数字表法将大鼠分为移植对照组(A组)、依达拉奉实验组(B组)、厄贝沙坦实验组(C组)、厄贝沙坦联合依达拉奉实验组(D组)及假手术对照组(E组).采用大鼠30％部分肝移植模型,按二袖套法进行大鼠原位肝移植.术后观察各组受鼠的存活情况,监测门静脉压和肝功能变化,术后6和24 h,检测移植肝组织内SOD活性及MDA含量,采用逆转录实时聚合酶链反应检测移植肝组织Egr-1 mRNA、ET-1 mRNA及Bax mRNA的表达,采用原位末端转移酶标记法检测移植肝细胞的凋亡情况.结果 术后7d,A、B、C、D及E组累积存活率分别为8.33 (1/12),33.3％(4/12),58.7％ (7/12),83.3％ (10/12)和100％(12/12),各组间差异均有统计学意义(P＜0.01).与对照组比较,各实验组门静脉压的变化,术后6和24 h的ALT和AST水平,MDA含量和SOD活性,Egr-1 mRNA、ET-1 mRNA及Bax mRNA的相对表达量,以及肝细胞凋亡指数等指标的检测结果均较优,尤以D组最为显著,各组间上述指标的两两比较,差异均有统计学意义(P＜0.05或P＜0.01).结论 联合使用厄贝沙坦和依达拉奉可通过降低门静脉压和抗氧化作用(减轻移植肝缺血再灌注损伤)的双重保护作用减轻大鼠小体积肝移植术后早期移植肝的损伤,且联合用药效果好于单用其中一种药物.
目的 探討聯閤使用阨貝沙坦和依達拉奉在大鼠小體積供肝移植早期中對移植肝的保護作用及機製.方法 取體重相差20～30g的150對SD大鼠作為肝移植供、受者,其中小體重大鼠作為供者.按隨機數字錶法將大鼠分為移植對照組(A組)、依達拉奉實驗組(B組)、阨貝沙坦實驗組(C組)、阨貝沙坦聯閤依達拉奉實驗組(D組)及假手術對照組(E組).採用大鼠30％部分肝移植模型,按二袖套法進行大鼠原位肝移植.術後觀察各組受鼠的存活情況,鑑測門靜脈壓和肝功能變化,術後6和24 h,檢測移植肝組織內SOD活性及MDA含量,採用逆轉錄實時聚閤酶鏈反應檢測移植肝組織Egr-1 mRNA、ET-1 mRNA及Bax mRNA的錶達,採用原位末耑轉移酶標記法檢測移植肝細胞的凋亡情況.結果 術後7d,A、B、C、D及E組纍積存活率分彆為8.33 (1/12),33.3％(4/12),58.7％ (7/12),83.3％ (10/12)和100％(12/12),各組間差異均有統計學意義(P＜0.01).與對照組比較,各實驗組門靜脈壓的變化,術後6和24 h的ALT和AST水平,MDA含量和SOD活性,Egr-1 mRNA、ET-1 mRNA及Bax mRNA的相對錶達量,以及肝細胞凋亡指數等指標的檢測結果均較優,尤以D組最為顯著,各組間上述指標的兩兩比較,差異均有統計學意義(P＜0.05或P＜0.01).結論 聯閤使用阨貝沙坦和依達拉奉可通過降低門靜脈壓和抗氧化作用(減輕移植肝缺血再灌註損傷)的雙重保護作用減輕大鼠小體積肝移植術後早期移植肝的損傷,且聯閤用藥效果好于單用其中一種藥物.
목적 탐토연합사용액패사탄화의체랍봉재대서소체적공간이식조기중대이식간적보호작용급궤제.방법 취체중상차20～30g적150대SD대서작위간이식공、수자,기중소체중대서작위공자.안수궤수자표법장대서분위이식대조조(A조)、의체랍봉실험조(B조)、액패사탄실험조(C조)、액패사탄연합의체랍봉실험조(D조)급가수술대조조(E조).채용대서30％부분간이식모형,안이수투법진행대서원위간이식.술후관찰각조수서적존활정황,감측문정맥압화간공능변화,술후6화24 h,검측이식간조직내SOD활성급MDA함량,채용역전록실시취합매련반응검측이식간조직Egr-1 mRNA、ET-1 mRNA급Bax mRNA적표체,채용원위말단전이매표기법검측이식간세포적조망정황.결과 술후7d,A、B、C、D급E조루적존활솔분별위8.33 (1/12),33.3％(4/12),58.7％ (7/12),83.3％ (10/12)화100％(12/12),각조간차이균유통계학의의(P＜0.01).여대조조비교,각실험조문정맥압적변화,술후6화24 h적ALT화AST수평,MDA함량화SOD활성,Egr-1 mRNA、ET-1 mRNA급Bax mRNA적상대표체량,이급간세포조망지수등지표적검측결과균교우,우이D조최위현저,각조간상술지표적량량비교,차이균유통계학의의(P＜0.05혹P＜0.01).결론 연합사용액패사탄화의체랍봉가통과강저문정맥압화항양화작용(감경이식간결혈재관주손상)적쌍중보호작용감경대서소체적간이식술후조기이식간적손상,차연합용약효과호우단용기중일충약물.
Objective To investigate the protective effect and mechanism of irbesartan and edaravone on the rat liver transplantation model using small-for-size graft during acute phase of reperfusion.Methods We used 300 S-D rats for small-for-size graft liver transplantation,and the light rats were used as donors.Survived recipients were divided into five groups according table of random number:group A,control group; group B,edaravone treatment group; group C,irbesartan treatment group; group D,irbesartan and edaravone treatment group; group E,sham operation group.The rat 30％ small-for-size graft model was established.Six rats in each group were sacrificed randomly at 6th and 24th h after reperfusion respectively. The survival rate of animals and portal pressure were investigated.The rats in every group were sacrificed and blood samples were collected for liver function measurement.The contents of SOD and MDA in liver tissues were measured.Fresh liver tissue was used to detect the mRNA expression of Egr-1,ET1 and Bax by RT-PCR. Paraffinembedded liver specimens were used to assay apoptosis (TUNEL).Six rats at each time point in each group were studied.Results (1) One-week survival rate in the groups A,B,C,D and E was 8.33％(1/12),33.3％ (4/12),58.7％ (7/12),83.3％ (10/12),and 100％ (12/12),respectively,P＜0.05; (2) There was significant difference in the portal pressure,ALT,AST,MDA,SOD,Egr-1,ET-1,Bax,and the apoptotic index between treatment groups and control group,especially in the group D,P＜0.05 or P＜0.01.Conclusion Irbesartan and edaravone could protect small-for-size graft in partial liver transplantation probably by reducing portal vein pressure and diminishing ischemia reperfusion injury.The combined use of Irbesartan and edaravone is more effective than irbesartan or edaravone used alone.
